Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jul;7(2):e001678.
doi: 10.1136/rmdopen-2021-001678.

Direct oral anticoagulants versus vitamin K antagonists in patients with antiphospholipid syndrome: systematic review and meta-analysis

Nazariy Koval  1 , Mariana Alves  2   3   4 , Rui Plácido  5   6 , Ana G Almeida  5   6 , João Eurico Fonseca  4   7 , Joaquim J Ferreira  2   4   8 , Fausto J Pinto  5   6 , Daniel Caldeira  9   5   6
Affiliations
Meta-Analysis

Direct oral anticoagulants versus vitamin K antagonists in patients with antiphospholipid syndrome: systematic review and meta-analysis

Nazariy Koval et al. RMD Open. 2021 Jul.

Abstract

Background: Despite vitamin K antagonists (VKA) being the gold standard in the prevention of thromboembolic events in antiphospholipid syndrome (APS), non-vitamin K antagonists oral anticoagulants/direct oral anticoagulants (DOACs) have been used off-label.

Objective: We aimed to perform a systematic review comparing DOACs to VKA regarding prevention of thromboembolic events, occurrence of bleeding events and mortality in patients with APS.

Methods: An electronic database search was performed through MEDLINE, CENTRAL and Web of Science. After data extraction, we pooled the results using risk ratio (RR) and 95% CI. Heterogeneity was assessed using the I². The outcomes considered were all thromboembolic events as primary, and major bleeding, all bleeding events and mortality as secondary. Evidence confidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation methodology.

Results: We included 7 studies and a total of 835 patients for analyses. Thromboembolic events were significantly increased in DOACs arm, compared with VKA-RR 1.69, 95% CI 1.09 to 2.62, I²-24%, n=719, 6 studies. In studies using exclusively rivaroxaban, which was the most representative drug in all included studies, the thromboembolic risk was increased threefold (RR 3.36, 95% CI 1.53 to 7.37). The risks of major bleeding, all bleeding events and mortality were not significantly different from control arm. The grade of certainty of our results is very low.

Conclusions: Current evidence suggests DOACs use, particularly rivaroxaban, among patients with APS, is less effective than VKA since it is associated with 69% increased risk of thromboembolic events.

Trial registration number: CRD42020216178.

Keywords: antiphospholipid syndrome; autoantibodies; autoimmune diseases.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Study flow chart.
Figure 2
Figure 2
Forest plot of the pooled analysis comparing DOACs vs VKA regarding TE events, major bleeding, all bleeding events and mortality. *Random effect, I²>50%. DOACs, direct oral anticoagulants; TE, thromboembolism; VKA, vitamin K antagonists.
See this image and copyright information in PMC

References

    1. Miyakis S, Lockshin MD, Atsumi T, et al. . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306. 10.1111/j.1538-7836.2006.01753.x - DOI - PubMed
    1. Keeling D, Mackie I, Moore GW, et al. . Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012;157:47–58. 10.1111/j.1365-2141.2012.09037.x - DOI - PubMed
    1. Tripodi A, de Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med 2011;270:110–22. 10.1111/j.1365-2796.2011.02362.x - DOI - PubMed
    1. Andreoli L, Chighizola CB, Banzato A, et al. . Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res 2013;65:1869–73. 10.1002/acr.22066 - DOI - PubMed
    1. Goldhaber SZ. Pulmonary embolism thrombolysis: a clarion call for international collaboration. J Am Coll Cardiol 1992;19:246–7. 10.1016/0735-1097(92)90473-Z - DOI - PubMed

MeSH terms

LinkOut - more resources